Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOB | P04114 | 9/20 | 0.56 |
| ▸ | MTTP | P55157 | 17/20 | 0.56 |
| ▸ | SMO | Q99835 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8212442 | 0.92 | APOB (0.54) | APOBMTTPSMOKDM4EALDH1A1 | |
| SCHEMBL8208323 | 0.89 | APOB (0.58) | APOBMTTPSMOKDM4EALDH1A1 | |
| SCHEMBL8200984 | 0.88 | APOB (0.62) | APOBMTTPSMOKDM4EALDH1A1 | |
| SCHEMBL8507709 | 0.88 | MTTP (0.58) | APOBMTTPSMOKDM4EALDH1A1 | |
| SCHEMBL8213608 | 0.88 | MTTP (0.60) | APOBMTTPSMOKDM4EALDH1A1 | |
| SCHEMBL8213404 | 0.88 | MTTP (0.58) | APOBMTTPSMOKDM4EALDH1A1 | |
| SCHEMBL4742408 | 0.88 | MTTP (0.58) | APOBMTTPSMOKDM4EALDH1A1 | |
| SCHEMBL8208665 | 0.87 | MTTP (0.57) | APOBMTTPSMOKDM4EALDH1A1 | |
| SCHEMBL8208329 | 0.87 | MTTP (0.57) | APOBMTTPSMOKDM4EALDH1A1 | |
| SCHEMBL8206849 | 0.86 | APOB (0.60) | APOBMTTPSMOKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1099442-A2 | Methods of administering apo B-secretion/MTP inhibitors | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| US-6121283-A | Apo B-secretion/MTP inhibitory amides | PFIZER INC (US) | 2000-09-19 | — | — | US | claimed |
| EP-0944602-A1 | APO B-SECRETION/MTP INHIBITORY AMIDES | PFIZER INC. (US) | 1999-09-29 | — | — | EP | claimed |
| WO-1998023593-A1 | APO B-SECRETION/MTP INHIBITORY AMIDES | PFIZER INC. (US) | 1998-06-04 | — | — | WO | claimed |
| US-9314438-B2 | Elevation of the plasma HDL-cholesterol level | AARHUS UNIVERSITET (DK) | 2016-04-19 | — | — | US | disclosed |
| EP-1951690-B1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-1954668-B9 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2094643-B1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-1954668-B1 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-28 | — | — | EP | disclosed |
| US-7919506-B2 | Dibenzyl amine compounds and derivatives | PFIZER INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20110038827-A1 | ELEVATION OF THE PLASMA HDL-CHOLESTEROL LEVEL | JEPPESEN, PER BENDIX (DK) | 2011-02-17 | — | — | US | disclosed |
| US-7888376-B2 | Cholesteryl ester transfer protein (CETP) inhibitors; atherosclerosis and cardiovascular diseases; N-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-4-(trifluoromethyl)thiazol-2-amine; Alzheimer's, atherosclerosis, venous thrombosis, peripheral vascular disease | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| US-7468378-B2 | Substituted quinoline compounds | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20050245570-A1 | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines | DENINNO MICHAEL P | 2005-11-03 | — | — | US | disclosed |
| US-20050234099-A1 | Substituted quinoline compounds | PFIZER INC | 2005-10-20 | — | — | US | disclosed |
| EP-1099442-A2 | Methods of administering apo B-secretion/MTP inhibitors | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
| US-6140343-A | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS WHICH ARE USED TO ELEVATE HIGHDENSITY LIPOPROTEIN-CHOLESTEROL AND TO LOWER LOW DENSITY LIPOPROTEIN-CHOLESTEROL AND TRIGLYCERIDES; FOR TREATING ATHEROSCLEROSIS, PERIPHERAL VASCULAR DISEASE, OBESITY | PFIZER (US) | 2000-10-31 | — | — | US | disclosed |
| US-6121283-A | Apo B-secretion/MTP inhibitory amides | PFIZER INC (US) | 2000-09-19 | — | — | US | disclosed |
| EP-0944602-A1 | APO B-SECRETION/MTP INHIBITORY AMIDES | PFIZER INC. (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998023593-A1 | APO B-SECRETION/MTP INHIBITORY AMIDES | PFIZER INC. (US) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245570-A1 | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines | CETP, APOB, HDLBP | APOB 2/4885MTTP 4/4885SMO 3709/4885 |
| US-20050234099-A1 | Substituted quinoline compounds | APOB, APOL1, MTPN | APOB 1/4885MTTP 9/4885SMO 4789/4885 |
| US-20110038827-A1 | ELEVATION OF THE PLASMA HDL-CHOLESTEROL LEVEL | CETP, CYP46A1, NPC1L1 | APOB 12/4885MTTP 5/4885SMO 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.